Technical Analysis for SABS - SAB Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | -1.11% | |
| New 52 Week Low | Weakness | -1.11% | |
| Earnings Movers | Other | -1.11% | |
| Gapped Down | Weakness | -1.11% | |
| Lower Bollinger Band Touch | Weakness | -1.11% | |
| Oversold Stochastic | Weakness | -1.11% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| Down 1% | about 17 hours ago |
| Fell Below 10 DMA | about 17 hours ago |
| 20 DMA Resistance | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/14/2024
SAB Biotherapeutics, Inc. Description
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Diabetes Infectious Diseases Antibodies Autoimmune Disease Antibody Immunotherapies Influenza Genetic Engineering Us Government Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.5 |
| 52 Week Low | 3.7201 |
| Average Volume | 10,128 |
| 200-Day Moving Average | 6.50 |
| 50-Day Moving Average | 4.56 |
| 20-Day Moving Average | 4.15 |
| 10-Day Moving Average | 4.03 |
| Average True Range | 0.26 |
| RSI (14) | 41.18 |
| ADX | 16.92 |
| +DI | 24.00 |
| -DI | 20.80 |
| Chandelier Exit (Long, 3 ATRs) | 4.15 |
| Chandelier Exit (Short, 3 ATRs) | 4.51 |
| Upper Bollinger Bands | 4.47 |
| Lower Bollinger Band | 3.84 |
| Percent B (%b) | 0.26 |
| BandWidth | 15.13 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.16 |
| MACD Histogram | 0.0134 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.00 | ||||
| Resistance 3 (R3) | 4.00 | 4.00 | 4.00 | ||
| Resistance 2 (R2) | 4.00 | 4.00 | 4.00 | 4.00 | |
| Resistance 1 (R1) | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Pivot Point | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Support 1 (S1) | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Support 2 (S2) | 4.00 | 4.00 | 4.00 | 4.00 | |
| Support 3 (S3) | 4.00 | 4.00 | 4.00 | ||
| Support 4 (S4) | 4.00 |
